| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,270,000 |
| Market
Cap: |
536.61(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.03 - $40.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fulgent Genetics is a holding company. Through its subsidiaries, Co. is a technology company providing COVID-19 testing services, molecular diagnostic testing services and genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. Co. has developed a proprietary technology platform allowing Co. to provide a test menu. Combining next generation sequencing with its technology platform, Co. performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet customer needs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
26,653 |
51,184 |
76,172 |
| Total Sell Value |
$0 |
$711,752 |
$1,535,512 |
$2,753,700 |
| Total People Sold |
0 |
3 |
3 |
4 |
| Total Sell Transactions |
0 |
4 |
16 |
33 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hsieh Ming |
President and CEO |
• • • |
2017-11-10 |
4 |
B |
$3.35 |
$31,403 |
D/D |
9,385 |
6,515,849 |
3.23 |
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2017-11-09 |
4 |
B |
$3.47 |
$40,029 |
D/D |
11,520 |
6,506,464 |
3.23 |
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2017-08-11 |
4 |
S |
$5.71 |
$35,017 |
D/D |
(6,134) |
388,602 |
|
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2017-06-15 |
4 |
B |
$5.35 |
$67,949 |
D/D |
12,700 |
6,494,944 |
3.23 |
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2017-06-14 |
4 |
B |
$5.11 |
$37,280 |
D/D |
7,300 |
6,482,244 |
3.23 |
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2017-06-13 |
4 |
B |
$5.01 |
$75,191 |
D/D |
15,000 |
6,474,944 |
3.23 |
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2017-06-12 |
4 |
B |
$4.95 |
$74,205 |
D/D |
15,000 |
6,459,944 |
3.23 |
- |
|
| Mulay James |
Director |
– • – |
2017-05-16 |
4/A |
A |
$0.00 |
$0 |
D/D |
2,000 |
10,000 |
|
- |
|
| Bolger John C |
Director |
– • – |
2017-05-16 |
4/A |
A |
$0.00 |
$0 |
D/D |
2,000 |
6,842 |
|
- |
|
| Fulgent Genetics, Inc. |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
10,000 |
|
- |
|
| Fulgent Genetics, Inc. |
Director |
– • – |
2017-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
6,842 |
|
- |
|
| Bolger John C |
Director |
– • – |
2016-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,842 |
4,842 |
|
- |
|
| Mulay James |
Director |
– • – |
2016-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
8,000 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – • |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,767,659 |
1,767,659 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – • |
2016-09-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,434,211) |
0 |
|
- |
|
| Xi Long Usa, Inc. |
10% Owner |
– – • |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,025,623 |
2,025,623 |
|
- |
|
| Yen Yun |
Director |
– • – |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
526,315 |
526,315 |
|
- |
|
| Yen Yun |
Director |
– • – |
2016-09-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,000,000) |
0 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
394,736 |
394,736 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2016-09-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,000,000) |
0 |
|
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2016-09-30 |
4 |
B |
$9.00 |
$9,000,000 |
D/D |
1,000,000 |
6,444,944 |
3.23 |
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,315,789 |
1,315,789 |
|
- |
|
| Hsieh Ming |
President and CEO |
• • • |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,444,944 |
5,444,944 |
|
- |
|
| Yen Yun |
Director |
– • – |
2016-09-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,000,000 |
|
- |
|
| Kim Paul |
CFO and TreasurerOfficer |
• – – |
2016-09-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500,000 |
|
- |
|
281 Records found
|
|
Page 11 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.39 (1.73%) 
